Top

Published in:

01-04-2016 | Original Article

A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma

Authors: Dongli Liu, Lili Dong, Yang Liu, Duo Wen, Dongmei Gao, Huichuan Sun, Jia Fan, Weizhong Wu

Published in: Tumor Biology | Issue 4/2016

Abstract

The molecular mechanisms that control metastasis of hepatocellular cancer (HCC) are still poorly understood. It has been determined that microRNA (miRNA) expression has tissue and cell specific, and decreased expression of specific miRNA could induce tumor genesis or metastasis. In this study, we identified that miR-17-5p was expressed lower in high metastatic capability HCC cell lines HCCLM3 and MHCC97H than low metastatic HCC cell line HepG2 by real-time (RT)-PCR. Restoration of miR-17-5p could significantly repress the invasiveness and metastasis of MHCC97H cell line. Furthermore, we validated c-Myc as a downstream and functional target of miR-17-5p using luciferase reporter assay. Immunohistochemical assay revealed that the expression of c-Myc protein levels was significantly increased in cancerous tissues compared with para-tumor tissues. After clinical data analysis, we observed that the higher level of c-Myc was significantly associated with a reduced overall survival (p = 0.0209). Consistent with previous research, we also demonstrated that c-Myc could upregulate the expression of miR-17-5p. Taken together, our data indicated that there is a regulatory feedback loop between miR-17-5p and c-Myc, in which miR-17-5p could suppress some of the distinguishing features, invasion, and metastasis, of oncogenic c-Myc in HCC cells, and meanwhile, miR-17-5p is upregulated by c-Myc role as a transcription factor, although further studies are still needed.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.CrossRefPubMed

Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–5. doi:10.1038/nature02871.CrossRefPubMed

Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMed

Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33. doi:10.1016/j.cell.2009.01.002.CrossRefPubMedPubMedCentral

Lujambio A, Lowe SW. The microcosmos of cancer. Nature. 2012;482(7385):347–55. doi:10.1038/nature10888.CrossRefPubMedPubMedCentral

Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinogenesis. 2012;33(6):1126–33. doi:10.1093/carcin/bgs140.CrossRefPubMedPubMedCentral

Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell. 2012;149(3):515–24. doi:10.1016/j.cell.2012.04.005.CrossRefPubMedPubMedCentral

Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008;22(20):2755–66. doi:10.1101/gad.1712408.CrossRefPubMedPubMedCentral

Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56–67. doi:10.1016/j.cell.2012.08.026.CrossRefPubMedPubMedCentral

10.

Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68–79. doi:10.1016/j.cell.2012.08.033.CrossRefPubMedPubMedCentral

11.

Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17(9):1115–29. doi:10.1101/gad.1067003.CrossRefPubMedPubMedCentral

12.

Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A. 2003;100(14):8164–9. doi:10.1073/pnas.1332764100.CrossRefPubMedPubMedCentral

13.

Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer. 2004;90(8):1612–9. doi:10.1038/sj.bjc.6601703.CrossRefPubMedPubMedCentral

14.

Planas-Silva MD, Bruggeman RD, Grenko RT, Smith JS. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer. Exp Mol Pathol. 2007;82(1):85–90. doi:10.1016/j.yexmp.2006.09.001.CrossRefPubMed

15.

Sierra A, Castellsague X, Escobedo A, Moreno A, Drudis T, Fabra A. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat. 1999;54(1):39–45.CrossRefPubMed

16.

Cairo S, Wang Y, de Reynies A, Duroure K, Dahan J, Redon MJ, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A. 2010;107(47):20471–6. doi:10.1073/pnas.1009009107.CrossRefPubMedPubMedCentral

17.

Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1–11.CrossRefPubMedPubMedCentral

18.

Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35. doi:10.1016/j.cell.2012.03.003.CrossRefPubMedPubMedCentral

19.

Bonauer A, Dimmeler S. The microRNA-17-92 cluster: still a miRacle? Cell Cycle. 2009;8(23):3866–73.CrossRefPubMed

20.

He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435(7043):828–33. doi:10.1038/nature03552.CrossRefPubMedPubMedCentral

21.

Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004;64(9):3087–95.CrossRefPubMed

22.

Ptashne M. Binding reactions: epigenetic switches, signal transduction and cancer. Curr Biol CB. 2009;19(6):R234–41. doi:10.1016/j.cub.2009.02.015.CrossRefPubMed

23.

Hitchler MJ, Domann FE. Metabolic defects provide a spark for the epigenetic switch in cancer. Free Radic Biol Med. 2009;47(2):115–27. doi:10.1016/j.freeradbiomed.2009.04.010.CrossRefPubMedPubMedCentral

24.

El Tayebi HM, Omar K, Hegy S, El Maghrabi M, El Brolosy M, Hosny KA, et al. Repression of miR-17-5p with elevated expression of E2F-1 and c-MYC in non-metastatic hepatocellular carcinoma and enhancement of cell growth upon reversing this expression pattern. Biochem Biophys Res Commun. 2013;434(3):421–7. doi:10.1016/j.bbrc.2013.04.003.CrossRefPubMed

25.

Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, et al. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol WJG. 2001;7(5):630–6.PubMed

26.

Sun FX, Tang ZY, Lui KD, Ye SL, Xue Q, Gao DM, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer J Int Du Cancer. 1996;66(2):239–43. doi:10.1002/(SICI)1097-0215(19960410)66:2<239::AID-IJC17>3.0.CO;2-7.CrossRef

27.

Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003;129(1):43–51. doi:10.1007/s00432-002-0396-4.PubMed

28.

Pi H, Xu S, Zhang L, Guo P, Li Y, Xie J, et al. Dynamin 1-like-dependent mitochondrial fission initiates overactive mitophagy in the hepatotoxicity of cadmium. Autophagy. 2013;9(11):1780–800. doi:10.4161/auto.25665.CrossRefPubMed

29.

Hu YJ, Li HY, Qiu KJ, Li DC, Zhou JH, Hu YH, et al. Downregulation of Notch1 inhibits the invasion of human hepatocellular carcinoma Hepg2 and MHCC97H cells through the regulation of PTEN and FAK. Int J Mol Med. 2014;34(4):1081–6. doi:10.3892/ijmm.2014.1889.PubMed

30.

Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX, et al. miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med. 2013;210(4):789–803. doi:10.1084/jem.20120153.CrossRefPubMedPubMedCentral

31.

Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401–14. doi:10.1016/j.cell.2007.04.040.CrossRefPubMedPubMedCentral

32.

Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(16):2707–16. doi:10.1200/JCO.2007.15.6521.CrossRef

33.

Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer. 2006;6(9):674–87. doi:10.1038/nrc1934.CrossRefPubMed

34.

Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006;103(24):9136–41. doi:10.1073/pnas.0508889103.CrossRefPubMedPubMedCentral

35.

Secombe J, Pierce SB, Eisenman RN. Myc: a weapon of mass destruction. Cell. 2004;117(2):153–6.CrossRefPubMed

36.

Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A. 2002;99(6):3830–5. doi:10.1073/pnas.062036999.CrossRefPubMedPubMedCentral

37.

Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O’Day E, et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3′UTR microRNA recognition elements. Mol Cell. 2009;35(5):610–25. doi:10.1016/j.molcel.2009.08.020.CrossRefPubMedPubMedCentral

38.

Lin F, Ding R, Zheng S, Xing D, Hong W, Zhou Z, et al. Decrease expression of microRNA-744 promotes cell proliferation by targeting c-Myc in human hepatocellular carcinoma. Cancer Cell Int. 2014;14:58. doi:10.1186/1475-2867-14-58.CrossRefPubMedPubMedCentral

Title: A c-Myc/miR-17-5p feedback loop regulates metastasis and invasion of hepatocellular carcinoma
Authors: Dongli Liu
Lili Dong
Yang Liu
Duo Wen
Dongmei Gao
Huichuan Sun
Jia Fan
Weizhong Wu
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4355-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway

Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC)

Long non-coding RNA MVIH is associated with poor prognosis and malignant biological behavior in breast cancer

Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma

MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway

Role of estrogen receptor alpha in human cervical cancer-associated fibroblasts: a transcriptomic study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer